From: Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients?
PJ | Placebo | P***for PJ vs. placebo at 12 m | ||||||
---|---|---|---|---|---|---|---|---|
N | Mean ± SD | P for trend | N | Mean ± SD | P for trend | |||
LDL mg/dl | 0 | 66 | 95.1 ± 31.5 | 0.07 | 35 | 95.8 ± 28.9 | 0.38 | 0.85 |
3 M | 98.9 ± 35.6 | 98.0 ± 28.1 | ||||||
6 M | 95.4 ± 32.4 | 91.8 ± 25.1 | ||||||
12 M | 100.0 ± 33.1 | 94.3 ± 27.2 | 0.39 | |||||
Total cholesterol mg/dl | 0 | 66 | 164.8 ± 37.1 | 0.27 | 35 | 163.5 ± 33.4 | 0.18 | 0.86 |
3 M | 167.7 ± 40.7 | 171.7 ± 35.1 | ||||||
6 M | 163.4 ± 38.9 | 164.8 ± 38.0 | ||||||
12 M | 167.3 ± 43.5 | 165.1 ± 35.8 | 0.79 | |||||
HDL mg/dl | 0 | 66 | 33.1 ± 9.5* | <0.001 | 35 | 36.6 ± 10.7 | 0.18 | 0.10 |
3 M | 37.2 ± 11.3 | 37.0 ± 11.7 | ||||||
6 M | 36.6 ± 10.9 | 37.3 ± 12.9 | ||||||
12 M | 36.8 ± 10.8 | 34.3 ± 15.4 | 0.40 | |||||
HDL ≤40 mg/dl at study initiation | 0 | 54 | 29.7 ± 5.7* | <0.001 | 23 | 30.2 ± 5.6 | 0.09 | 0.84 |
3 M | 33.8 ± 7.8 | 31.2 ± 7.6 | ||||||
6 M | 33.6 ± 7.7 | 31.8 ± 10.2 | ||||||
12 M | 33.6 ± 7.5 | 27.6 ± 11.6 | 0.03 | |||||
TG mg/dl | 0 | 66 | 183.6 ± 101.6** | 0.05 | 35 | 176.7 ± 86.7 | 0.04 | 0.73 |
3 M | 175.7 ± 90.8 | 192.9 ± 100.7 | ||||||
6 M | 174.0 ± 89.8 | 193.6 ± 90.5 | ||||||
12 M | 167.3 ± 86.3 | 206.1 ± 109.4 | 0.05 | |||||
TG ≥200 mg/dl at study initiation | 0 | 20 | 310.1 ± 87.8** | 0.02 | 10 | 288.1 ± 71.9 | 0.15 | 0.13 |
3 M | 267.3 ± 86.6 | 318.2 ± 96.6 | ||||||
6 M | 248.7 ± 100.5 | 301.5 ± 78.2 | ||||||
12 M | 237.4 ± 102.5 | 320.4 ± 56.8 | 0.008 |